Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function.
Two recent randomized trials pointed out the beneficial effect of enzyme replacement therapy on biochemical parameters in patients with Anderson-Fabry's disease. Clinical end-points, such as amelioration or stabilization of renal function deterioration, or improvement of left ventricular hypertrophy have not been evaluated in depth. We report the case of a patient whose moderately impaired renal function was stabilized with the start of enzyme treatment. In addition, left ventricular hypertrophy tended to regress. To our knowledge this is the first observation of clinical efficacy of the enzyme replacement therapy in Anderson-Fabry's disease in patients with moderately impaired renal function.
De Schoenmakere
Gert
G
Service de Néphrologie, Hôpital Necker, Paris, France.
Chauveau
Dominique
D
Grünfeld
Jean-Pierre
JP
D000328:Adult; D003404:Creatinine / Q000097:blood; D057487:Enzyme Therapy; D000795:Fabry Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D000519:alpha-Galactosidase / Q000627:therapeutic use*
D007527:Isoenzymes; D011994:Recombinant Proteins; D003404:Creatinine; D000519:alpha-Galactosidase; C459420:agalsidase beta